-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Nurix Therapeutics, Maintains $26 Price Target

Benzinga·04/08/2026 17:18:15
Listen to the news
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $26 price target.